Prevalence of Sexually Transmitted Infections (STIs) and Coinfections in the General Population
ConditionHIV Infections
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCerbaXpert
About this trial
Prevalence of Sexually Transmitted Infections (STIs) and co-infections in the general population
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Subject, male or female, 18 years of age or older
Subject capable of understanding the purpose of the research having given their free and informed written consent
Subject presenting to the laboratory for a biological examination
Affiliated subject or beneficiary of a social security scheme
Disqualifiers
None
Trial population
A cohort of 9,000 participants meeting all the inclusion criteria will be recruited. A participant identification list will be created and maintained at clinical investigation sites, linking the participant's personal data to the code assigned in the research. The identification list of participants will be kept on the research site in paper or digital format classified in the investigator binder.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Blood sample
Diagnostic testBlood sample
Treatment groups
9,000 Participants
are divided into 1 treatment groupGroup A: Adults1 intervention
Trial outcomes
Primary outcomes
1
The prevalence of each STI will be assessed by the participant's positive or negative status for each pathogen, determined by the following screening tests:
HIV testing is based on finding antibodies to HIV-1 and HIV-2 and P24 antigen of the virus; * Hepatitis B screening is based on HBsAg (hepatitis B surface antigen) research; * Herpes screening is based on testing for antibodies to Herpes Simplex virus (HSV-1 and HSV-2); * Papilloma virus screening is based on the HPV-HR test from a smear on the cervix; * Chlamydia screening is based on a nucleic acid amplification (NAAT) test; * Gonorrhea screening is based on the identification of the bacteria on a urine sample or secretions from the vagina or cervix; * Screening for trichomoniasis is based on a molecular diagnosis that involves identifying the parasite's DNA from a genital or urinary sample; * The detection of syphilis is based on antibody research.
Time frame
3 yearsLocations
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: